RT Journal
A1 Kuehn BM
T1 HIv, hepatitis drug interactions
JF JAMA
JO JAMA
YR 2012
FD March 28
VO 307
IS 12
SP 1243
OP 1243
DO 10.1001/jama.2012.332
UL http://dx.doi.org/10.1001/jama.2012.332
AB 
Citing evidence from a pharmacokinetic study, the FDA warned that patients taking the hepatitis C–targeted protease inhibitor boceprevir along with any of the ritonavir-boosted HIV-targeting protease inhibitors atazanavir, darunavir, or lopinavir may have lower blood levels of 1 or both drugs. The label of boceprevir will be updated to indicate this potential interaction, and the drug's manufacturer has sent letters to warn physicians.